成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook
Chinese English Germany Korean

Shanghai Yifei Biotechnology Co. , Ltd. 企業(yè)の連絡(luò)先情報(bào)

名前:Shanghai Yifei Biotechnology Co. , Ltd.
電話番號(hào):021-65675885
電子メール:customer_service@efebio.com
國(guó)籍:China
ウェブサイト:http://www.efebio.com
商品の合計(jì)數(shù):11974
94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120

製品カタログ

TL12-1862250025-88-6C44H51ClN10O9S
MEISi-22250156-71-7C18H14N2O3
IR820-PTX2250419-19-1
Pirepemat fumarate2251806-70-7C15H17F2NO5
Aβ/tau aggregation-IN-12252162-81-3C25H21IN2O
RAS GTPase inhibitor 12252242-32-1C27H28ClF4N5O2
Sabatolimabサバトリマブ（遺伝子組換え）2252262-24-9
Oditrasertib2252271-93-3C14H15F2N3O2
Feladilimabフェラジリマブ（遺伝子組換え）2252518-85-5
Pimicotinib2253123-16-7C22H24N6O3
SY-LB-572253719-35-4C16H13N3O
BCL6-IN-32253878-44-1C24H31ClF2N6O2
bisSP12253947-15-6C12H23N9O2
(2′S)-4′-O-β-D-apiofuranosyl-(1→6)-O-β-D-glucopyranosylvisamminol2254096-97-2C26H34O14
Upifitamab2254118-43-7
NLRP3-IN-172254432-75-0C21H22N4O2S
AMPC2254434-33-6C25H16FN3O3
Fenitrooxoneりん酸O,O-ジメチルO-(3-メチル-4-ニトロフェニル)2255-17-6C9H12NO6P
Bafrekalant2256770-44-0C29H31ClN6O2
Isothiuronium2-(10-ウンデセニル)イソチオ尿素·よう化水素酸塩22584-04-9C12H25IN2S
Bexmarilimab2259301-27-2
Rosopatamab2260767-49-3
OSMI-32260791-13-5C32H35N3O9S2
USP15-IN-12260826-16-0C22H23N3O3
TH-Z1452260887-57-6C16H28O7P2
S21572262488-39-9C23H28ClF2N3O2
4-PQBH2243355-51-1C22H17N5O
PARP1/2/TNKS1/2-IN-12243453-32-7
DNDI-61482243909-59-1C16H14BN5O3
2-Quinoxalinecarboxylic acid-d42244217-89-6C9H6N2O2
3-Methyl-2-quinoxalinecarboxylic Acid-d42244217-93-2C10H4D4N2O2
Amine-PEG3-Lys(PEG3-N3)-PEG3-N32244602-35-3C30H58N10O12
Cudarolimab2244739-29-3
Idactamab2245205-37-0
Pirmitegravir2245231-10-9C27H31ClN4O3
GSK-2807 free base(2S)-2-アミノ-4-[3-(ジメチルアミノ)プロピル(5′-アデノシル)アミノ]ブタン酸2245255-65-4C19H32N8O5
ARX-17962245880-46-8C14H23N3O8S
Janelia Fluor 549 TFA2245946-45-4C29H23F3N2O7
Tubulin inhibitor 352247047-77-2
Adebrelimab2247114-85-6
BY272247236-59-3C22H21ClN6
AW682247236-61-7
ITF37562247608-27-9C13H11N5O2S
AHR antagonist 52247953-39-3C25H25ClFN7
STAT3-IN-132248552-86-3C21H20N6O3S
Ziltivekimab2226654-05-1
Itepekimab2226742-52-3
Tilvestamab2226775-26-2
UNC52932226789-82-6C30H42N6O2
Favezelimab2231068-83-8
BI-14082231075-94-6C22H23FN6
ALDH1A1-IN-22231081-18-6C25H23ClN4O3S
NCT-5062231098-99-8C25H23FN4O3S
Opevesostat2231294-96-3C21H26N2O5S
Vibostolimab (anti-TIGIT)2231305-30-7
BMT-090605 hydrochloride2231664-45-0C21H25ClN4O2
AZ22231760-33-9C20H23N3O2S
SHR16532231770-73-1C21H21ClFN5O2
EMT inhibitor-22232228-60-1C24H26N2O8
PDDC inhibitor2232878-43-0C27H29N5O4
AP-C52234272-10-5C16H13N5
(Iso)-Atagabalin HCl223445-68-9
HDAC6 degrader 9c2235382-05-3C37H45N9O10
ERα degrader-22235396-63-9C29H27F3N2O2
Nampt activator-22237268-90-3C17H15ClN4O3S
DMA-135 hydrochloride2237925-62-9C16H18ClN7O
22393-62-0_peak 2(Z)-1-ブロモ-1,2-ジフェニル-2-(p-エチルフェニル)エテン22393-63-1C22H19Br
Hu7691 free base2241232-43-7C22H21F3N4O
BTK inhibitor 102241732-30-7C25H23N5O3
MMP-9-IN-62241964-36-1C25H19NO2
Vixarelimab2243320-83-2
CFTR corrector 62226970-01-8C22H13F4N9
CXCR7 modulator 22227426-37-9C29H42N6O3
Mezagitamab2227490-52-8
HPK1-IN-192227609-33-6C27H32N7O2P
Ragaglitazar222834-30-2C25H25NO5
HPK1-IN-262229042-24-2C19H21N5OS
ZL04542229042-77-5C18H22N4O3S
Glofitamab2229047-91-8
Avizakimab2229685-51-0
Mirzotamab2229859-11-2
Revdofilimab2230138-89-1
KDM4-IN-42230475-63-3C16H23NO
JNJ-653553942230598-99-7C19H26N4OS
RORγt inverse agonist 232230779-18-5C26H33NO5S
EHMT2-IN-12230849-55-3C18H23N7O
Serplulimab2231029-82-4
Ar-V7-IN-12230880-25-6C10H10Br2N4OS
Nrf2 activator-12230697-41-1C30H34N4O6S
Lorpucitinib2230282-02-5C22H28N6O2
Alogabat2230009-48-8C21H23N5O4
GSK-3 inhibitor 32227279-84-5C23H15FN6O
GSK-3 inhibitor 42227279-83-4C22H15F2N5O
Tesnatilimab2242758-08-1
AUTAC12241669-09-8C44H63FN8O11S
LY33726892241514-56-5C16H22FN5O3S
Triflubazamトリフルバザム22365-40-8C17H13F3N2O2
Atagabalin HCl223445-67-8C10H20ClNO2
cpd.5 of 2234271-86-22234284-82-1C12H11NO3
94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
Copyright 2017 ? ChemicalBook. All rights reserved